Host-Cell Proteins: Implications for Protein-Drug Efficacy - BioProcess InternationalBioProcess International
Por um escritor misterioso
Descrição
Host cell protein content is often identified as a critical quality attribute and is often used as a benchmark during biologics manufacturing.
Posttranslational Modifications and Their Control in CHO Culture - BioProcess InternationalBioProcess International
What are Host Cell Proteins and Its Effect on Biopharmaceutical Development - Creative Proteomics
Featured Reports - BioProcess InternationalBioProcess International
Host-Cell Protein Risk Management and Control During Bioprocess Development: A Consolidated Biotech Industry Review, Part 1 - BioProcess InternationalBioProcess International
Quality By Design for Monoclonal Antibodies, Part 2: Process Design Space and Control Strategies - BioProcess InternationalBioProcess International
PDF) Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development
Best practices & strategies for biotherapeutics production using a stable scale-up process - Aragen Life Sciences
Control of Host Cell Proteins in Monoclonal-Antibody Bioprocessing - BioProcess InternationalBioProcess International
Exploring sample preparation and data evaluation strategies for enhanced identification of host cell proteins in drug products of therapeutic antibodies and Fc-fusion proteins
Page 79 – BioProcess InternationalBioProcess International, Covering the whole development process for the global biotechnology industry
Risk-Assessment Framework for Managing Host-Cell Proteins - BioProcess InternationalBioProcess International
Host Cell Proteins The Bioprocessing Summit
Full article: Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development
Host Cell Protein Analysis: From Process to Advances to Future
PDF) Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development
de
por adulto (o preço varia de acordo com o tamanho do grupo)
